01:42 , May 4, 2016 |  BC Extra  |  Financial News

MVM closes fourth fund at $233M

MVM Life Science Partners closed its fourth fund, MVM IV, at $233 million. The firm said it will invest $15-$30 million per company in healthcare companies of all stages in the U.S. and Europe. MVM...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Financial News

bioTheranostics completes venture financing

bioTheranostics Inc. , San Diego, Calif.   Business: Diagnostic   Date completed: 2016-01-21   Type: Venture financing   Raised: $32 million   Investors: MVM Life Science Partners; Canepa Advanced Healthcare; HealthQuest Capital  ...
02:09 , Jan 22, 2016 |  BC Extra  |  Financial News

bioMerieux spinout bioTheranostics raises $32M

bioTheranostics Inc. raised $32 million in an equity round and said it will spin out from parent company bioMerieux S.A. (Euronext:BIM). MVM Life Science Partners led the round, in which Canepa Advanced Healthcare Fund and...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

bioMerieux, Celsee deal

bioMerieux’s bioTheranostics Inc. subsidiary partnered with Celsee to investigate the technical feasibility of using bioTheranostics’ biomarkers for molecular characterization of circulating tumor cells (CTCs) enriched and captured with Celsee’s Jetta CTC platform in proof-of-concept (POC)...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

Breast Cancer Index regulatory update

BioMerieux's Biotheranostics Inc. company said CMS posted a positive coverage and reimbursement policy for the Breast Cancer Index to determine the risk of early and late recurrence and benefit from extended endocrine therapy in patients...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

bioMerieux management update

bioMerieux S.A. (Euronext:BIM), Marcy l'Etoile, France   Business: Diagnostic, Pharmacogenetics   Hired: Nicolas Barthelemy as president and CEO of bioMerieux's bioTheranostics Inc. subsidiary, formerly chief commercial officer and president of the cell systems division at...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Breast Cancer Index regulatory update

bioMerieux’s bioTheranostics Inc. company said the New York State Department of Health approved the company’s Breast Cancer Index (BCI) to determine the risk of early and late recurrence and benefit from extended endocrine therapy in...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

bioMerieux sales and marketing update

bioMerieux’s bioTheranostics Inc. subsidiary said U.S. healthcare provider FedMed Inc. will cover genomic tests for patients with breast cancer and metastatic cancers. bioTheranostics said that FedMed has a preferred provider network that includes more than...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Breast Cancer Index diagnostic data

Researchers at Massachusetts General Hospital and colleagues reported data from 665 postmenopausal women with estrogen receptor-positive breast cancer in a prospective comparative study showing that only the BCI predicts risk for both early (0-5 years)...
00:25 , Sep 13, 2013 |  BC Extra  |  Clinical News

Researchers compare diagnostics that predict breast cancer recurrence

Researchers at Massachusetts General Hospital reported data from a prospective comparative study showing that only Breast Cancer Index (BCI) from the bioTheranostics Inc. subsidiary of bioMerieux S.A. (Euronext:BIM) predicts risk for both early (0-5 years)...